Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole

Autores
Sanabria, Rodrigo Eduardo Fabrizio; Ceballos, Laura; Moreno, Laura; Romero, Jorge Marcelo; Lanusse Carlos; Alvarez, Luis Ignacio
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The experiments described here were designed to characterize the status of susceptibility/resistance to albendazole (ABZ) and triclabendazole (TCBZ) of a Fasciola hepatica isolate (named CEDIVE isolate) recovered from infected sheep (Gualeguay, Argentina) and maintained under laboratory conditions. Two separate clinical efficacy experiments were performed on sheep artificially infected with the CEDIVE isolate. Experiment 1: Sheep were randomly distributed either in an untreated control group or an ABZ (7.5 mg/kg) treated group (n= 4 each). Additionally, the systemic exposure of ABZ metabolites was assessed in those ABZ-treated infected animals. In Experiment 2, an untreated control group and a TCBZ (10 mg/kg) treated group was included (n = 4 each). The fluckicidal efficacy of ABZ and TCBZ was assessed by comparison of the number of flukes recovered from untreated and treated sheep at 15 days post-treatment. The efficacy against the CEDIVE isolate of F. hepatica was 29% (ABZ) and 100% (TCBZ). The plasma drug exposure (expressed as AUC and Cmax) observed in the ABZ treated animals (Experiment 1), was in agreement with data obtained in previous studies, which indicate that the low ABZ efficacy was not related to the quality of the pharmaceutical product and/or to a low systemic availability of the active drug/metabolite. The results reported here, clearly show that the CEDIVE isolate of F. hepatica behaves as resistant to ABZ and susceptible to TCBZ.
Fil: Sanabria, Rodrigo Eduardo Fabrizio. Universidad Nacional de la Plata. Facultad de Ciencias Veterinarias; Argentina
Fil: Ceballos, Laura. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
Fil: Moreno, Laura. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
Fil: Romero, Jorge Marcelo. Universidad Nacional de la Plata. Facultad de Ciencias Veterinarias; Argentina
Fil: Lanusse Carlos. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
Fil: Alvarez, Luis Ignacio. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
Materia
Fasciola Hepatica Isolate
Resistance
Albendazole
Triclabendazole
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/992
Acceder
id CONICETDig_92b9dc1c3314bb50eced615ca34572db
oai_identifier_str oai:ri.conicet.gov.ar:11336/992
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazoleSanabria, Rodrigo Eduardo FabrizioCeballos, LauraMoreno, LauraRomero, Jorge MarceloLanusse CarlosAlvarez, Luis IgnacioFasciola Hepatica IsolateResistanceAlbendazoleTriclabendazolehttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4The experiments described here were designed to characterize the status of susceptibility/resistance to albendazole (ABZ) and triclabendazole (TCBZ) of a Fasciola hepatica isolate (named CEDIVE isolate) recovered from infected sheep (Gualeguay, Argentina) and maintained under laboratory conditions. Two separate clinical efficacy experiments were performed on sheep artificially infected with the CEDIVE isolate. Experiment 1: Sheep were randomly distributed either in an untreated control group or an ABZ (7.5 mg/kg) treated group (n= 4 each). Additionally, the systemic exposure of ABZ metabolites was assessed in those ABZ-treated infected animals. In Experiment 2, an untreated control group and a TCBZ (10 mg/kg) treated group was included (n = 4 each). The fluckicidal efficacy of ABZ and TCBZ was assessed by comparison of the number of flukes recovered from untreated and treated sheep at 15 days post-treatment. The efficacy against the CEDIVE isolate of F. hepatica was 29% (ABZ) and 100% (TCBZ). The plasma drug exposure (expressed as AUC and Cmax) observed in the ABZ treated animals (Experiment 1), was in agreement with data obtained in previous studies, which indicate that the low ABZ efficacy was not related to the quality of the pharmaceutical product and/or to a low systemic availability of the active drug/metabolite. The results reported here, clearly show that the CEDIVE isolate of F. hepatica behaves as resistant to ABZ and susceptible to TCBZ.Fil: Sanabria, Rodrigo Eduardo Fabrizio. Universidad Nacional de la Plata. Facultad de Ciencias Veterinarias; ArgentinaFil: Ceballos, Laura. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; ArgentinaFil: Moreno, Laura. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; ArgentinaFil: Romero, Jorge Marcelo. Universidad Nacional de la Plata. Facultad de Ciencias Veterinarias; ArgentinaFil: Lanusse Carlos. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; ArgentinaFil: Alvarez, Luis Ignacio. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; ArgentinaElsevier Science Bv2013-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/992Sanabria, Rodrigo Eduardo Fabrizio; Ceballos, Laura; Moreno, Laura; Romero, Jorge Marcelo; Lanusse Carlos; et al.; Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole; Elsevier Science Bv; Veterinary Parasitology; 193; 5-2013; 105-1100304-4017enginfo:eu-repo/semantics/altIdentifier/url/http://www.ncbi.nlm.nih.gov/pubmed/23273779info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:09:50Zoai:ri.conicet.gov.ar:11336/992instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:09:50.446CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
title Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
spellingShingle Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
Sanabria, Rodrigo Eduardo Fabrizio
Fasciola Hepatica Isolate
Resistance
Albendazole
Triclabendazole
title_short Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
title_full Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
title_fullStr Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
title_full_unstemmed Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
title_sort Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole
dc.creator.none.fl_str_mv Sanabria, Rodrigo Eduardo Fabrizio
Ceballos, Laura
Moreno, Laura
Romero, Jorge Marcelo
Lanusse Carlos
Alvarez, Luis Ignacio
author Sanabria, Rodrigo Eduardo Fabrizio
author_facet Sanabria, Rodrigo Eduardo Fabrizio
Ceballos, Laura
Moreno, Laura
Romero, Jorge Marcelo
Lanusse Carlos
Alvarez, Luis Ignacio
author_role author
author2 Ceballos, Laura
Moreno, Laura
Romero, Jorge Marcelo
Lanusse Carlos
Alvarez, Luis Ignacio
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Fasciola Hepatica Isolate
Resistance
Albendazole
Triclabendazole
topic Fasciola Hepatica Isolate
Resistance
Albendazole
Triclabendazole
purl_subject.fl_str_mv https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
dc.description.none.fl_txt_mv The experiments described here were designed to characterize the status of susceptibility/resistance to albendazole (ABZ) and triclabendazole (TCBZ) of a Fasciola hepatica isolate (named CEDIVE isolate) recovered from infected sheep (Gualeguay, Argentina) and maintained under laboratory conditions. Two separate clinical efficacy experiments were performed on sheep artificially infected with the CEDIVE isolate. Experiment 1: Sheep were randomly distributed either in an untreated control group or an ABZ (7.5 mg/kg) treated group (n= 4 each). Additionally, the systemic exposure of ABZ metabolites was assessed in those ABZ-treated infected animals. In Experiment 2, an untreated control group and a TCBZ (10 mg/kg) treated group was included (n = 4 each). The fluckicidal efficacy of ABZ and TCBZ was assessed by comparison of the number of flukes recovered from untreated and treated sheep at 15 days post-treatment. The efficacy against the CEDIVE isolate of F. hepatica was 29% (ABZ) and 100% (TCBZ). The plasma drug exposure (expressed as AUC and Cmax) observed in the ABZ treated animals (Experiment 1), was in agreement with data obtained in previous studies, which indicate that the low ABZ efficacy was not related to the quality of the pharmaceutical product and/or to a low systemic availability of the active drug/metabolite. The results reported here, clearly show that the CEDIVE isolate of F. hepatica behaves as resistant to ABZ and susceptible to TCBZ.
Fil: Sanabria, Rodrigo Eduardo Fabrizio. Universidad Nacional de la Plata. Facultad de Ciencias Veterinarias; Argentina
Fil: Ceballos, Laura. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
Fil: Moreno, Laura. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
Fil: Romero, Jorge Marcelo. Universidad Nacional de la Plata. Facultad de Ciencias Veterinarias; Argentina
Fil: Lanusse Carlos. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
Fil: Alvarez, Luis Ignacio. Universidad Nacional del Centro de la Provincia de Buenos Aires.. Facultad de Ciencias Veterinarias. Departamento de Fisiopatologia. Laboratorio de Farmacologia; Argentina
description The experiments described here were designed to characterize the status of susceptibility/resistance to albendazole (ABZ) and triclabendazole (TCBZ) of a Fasciola hepatica isolate (named CEDIVE isolate) recovered from infected sheep (Gualeguay, Argentina) and maintained under laboratory conditions. Two separate clinical efficacy experiments were performed on sheep artificially infected with the CEDIVE isolate. Experiment 1: Sheep were randomly distributed either in an untreated control group or an ABZ (7.5 mg/kg) treated group (n= 4 each). Additionally, the systemic exposure of ABZ metabolites was assessed in those ABZ-treated infected animals. In Experiment 2, an untreated control group and a TCBZ (10 mg/kg) treated group was included (n = 4 each). The fluckicidal efficacy of ABZ and TCBZ was assessed by comparison of the number of flukes recovered from untreated and treated sheep at 15 days post-treatment. The efficacy against the CEDIVE isolate of F. hepatica was 29% (ABZ) and 100% (TCBZ). The plasma drug exposure (expressed as AUC and Cmax) observed in the ABZ treated animals (Experiment 1), was in agreement with data obtained in previous studies, which indicate that the low ABZ efficacy was not related to the quality of the pharmaceutical product and/or to a low systemic availability of the active drug/metabolite. The results reported here, clearly show that the CEDIVE isolate of F. hepatica behaves as resistant to ABZ and susceptible to TCBZ.
publishDate 2013
dc.date.none.fl_str_mv 2013-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/992
Sanabria, Rodrigo Eduardo Fabrizio; Ceballos, Laura; Moreno, Laura; Romero, Jorge Marcelo; Lanusse Carlos; et al.; Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole; Elsevier Science Bv; Veterinary Parasitology; 193; 5-2013; 105-110
0304-4017
url http://hdl.handle.net/11336/992
identifier_str_mv Sanabria, Rodrigo Eduardo Fabrizio; Ceballos, Laura; Moreno, Laura; Romero, Jorge Marcelo; Lanusse Carlos; et al.; Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole; Elsevier Science Bv; Veterinary Parasitology; 193; 5-2013; 105-110
0304-4017
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.ncbi.nlm.nih.gov/pubmed/23273779
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science Bv
publisher.none.fl_str_mv Elsevier Science Bv
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270095734210560
score 13.13397

Publicaciones similares